Panbela Therapeutics Ano de IPO
Qual é o Ano de IPO de Panbela Therapeutics?
O Ano de IPO de Panbela Therapeutics Inc. é 2020
Qual é a definição de Ano de IPO?
A oferta pública inicia (OPI)l é um tipo de oferta pública em que as ações de uma empresa geralmente são vendidas a investidores institucionais que, por sua vez, vendem para o público em geral, em uma bolsa de valores, pela primeira vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Ano de IPO de empresas na Setor Health Care em NASDAQ em comparação com Panbela Therapeutics
O que Panbela Therapeutics faz?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Empresas com ano de ipo semelhantes a Panbela Therapeutics
- Acusensus Ltd tem Ano de IPO de 2019
- Grayscale Ethereum Trust (ETH) tem Ano de IPO de 2019
- Powerwrap Ltd tem Ano de IPO de 2019
- Powerwrap tem Ano de IPO de 2019
- National Rural Utilities Cooper tem Ano de IPO de 2019
- Listed Funds Trust tem Ano de IPO de 2019
- Panbela Therapeutics tem Ano de IPO de 2020
- Globally Local Technologies tem Ano de IPO de 2021
- uniQure N.V tem Ano de IPO de 2021
- Trustpilot plc tem Ano de IPO de 2021
- IQVIA tem Ano de IPO de 2021
- ACTIA S.A tem Ano de IPO de 2021
- Remark tem Ano de IPO de 2021